The future of cancer treatment: will it include immunotherapy?
- PMID: 22789534
- DOI: 10.1016/j.ccr.2012.06.009
The future of cancer treatment: will it include immunotherapy?
Abstract
Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells.
Copyright © 2012 Elsevier Inc. All rights reserved.
Comment on
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2. N Engl J Med. 2012. PMID: 22658127 Free PMC article. Clinical Trial.
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2. N Engl J Med. 2012. PMID: 22658128 Free PMC article. Clinical Trial.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
